Allergan prevails in Acular litigation

Apotex barred from introducing its generic version of the ocular inflammatory agent Acular (ketorolac ophthalmic solution) until 2009 after a San Francisco federal judge upholds the validity of an Allergan/ Syntex patent and finds Apotex' ANDA infringed. Apotex subsequently dismissed separate antitrust claims that hinge on the patent case. Apotex said it will appeal the patent ruling and could refile the anticompetition claims. FTC inquiry into Allergan's conduct with regard to Acular generics is ongoing (1"The Pink Sheet" Aug. 18, 2003, p. 14)...